Liquid Biopsy Assay Can Predict CRC Recurrence Early

Patients testing positive for any of six ctDNA biomarkers on the liquid biopsy assay had a substantially higher risk for colorectal cancer recurrence.

Related Keywords

Houston ,Texas ,United States ,China ,California ,Spain ,Santiago De Compostela ,Galicia ,Juan Ruiz Ba ,Kevan Morris ,Ajay Goel ,Shaobo Mo ,Fudan University Shanghai Cancer Center ,University Of Santiago De Compostela ,Morris ,City Of Hope Comprehensive Cancer Center ,University Of Texas Md Anderson Cancer Center ,Cancer Center ,Hope Comprehensive Cancer Center ,Colorectal Cancer ,Disease Recurrence ,Liquid Biopsy ,Luid Biopsy ,Luid Phase Biopsy ,Cancer Blood Test ,Ancer Saliva Test ,Lood Biopsy ,Erum Biopsy ,Preventive Oncology ,Adjuvant Chemotherapy ,Biopsy ,Methylation ,Genomics ,Genomic Medicine ,Edicine Genomic ,Biologic Therapy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Chemotherapy ,Biomarker ,Iological Marker ,Postoperative ,Surgery ,Blood ,Tumor ,Adjuva ,